Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation

Non-valvular atrial fibrillation is becoming more common in Australia and globally The direct oral anticoagulants apixaban, dabigatran and rivaroxaban offer an improved safety profile over warfarin Patient preferences are important and shared decision-making supports better adherence to treatment

Detalles Bibliográficos
Autor principal: Lindley, Richard I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: NPS MedicineWise 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075749/
https://www.ncbi.nlm.nih.gov/pubmed/33911332
http://dx.doi.org/10.18773/austprescr.2021.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075749/
https://www.ncbi.nlm.nih.gov/pubmed/33911332
http://dx.doi.org/10.18773/austprescr.2021.002

Ejemplares similares